Dr. Arvind R. Cavale, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Years since graduation
- 36
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 481
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
PA license MD052765L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hospital of Univ of Pennsylvania Philadelphia, PA
- Doylestown Hospital Doylestown, PA
- St Mary Medical Center Langhorne, PA
- Holy Redeemer Hospital and Medical Center Meadowbrook, PA
- Nazareth Hospital Philadelphia, PA
Medical groups
- Diabetes and Endocrinology Consultants of Pennsylvania LLC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 481
- Services billed
- 2,544
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 1,036 | 202 |
| Established patient office or other outpatient visit, 20-29 minutes | 544 | 332 |
| Established patient office or other outpatient visit, 30-39 minutes | 538 | 330 |
| New patient office or other outpatient visit, 60-74 minutes | 54 | 54 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 34 | 33 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | 31 | 31 |
| Established patient office or other outpatient visit, 40-54 minutes | 15 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Feasterville Trevose, PA | 968 |
| Repaglinide | 681 |
| Mounjaro (tirzepatide) Other prescribers in Feasterville Trevose, PA | 379 |
| Rosuvastatin Calcium Other prescribers in Feasterville Trevose, PA | 375 |
| Synthroid (levothyroxine sodium) Other prescribers in Feasterville Trevose, PA | 322 |
| Metformin Hcl Other prescribers in Feasterville Trevose, PA | 308 |
| Trijardy Xr (empaglifloz/linaglip/metformin) | 250 |
| Trulicity (dulaglutide) Other prescribers in Feasterville Trevose, PA | 248 |
| Novolog Flexpen (insulin aspart) Other prescribers in Feasterville Trevose, PA | 197 |
| Jardiance (empagliflozin) Other prescribers in Feasterville Trevose, PA | 164 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 10 payments worth $5,973 in total to this clinician.
| Ascendis Pharma Endocrinology Inc | $5,928 |
|---|---|
| Alexion Pharmaceuticals, Inc. | $18.90 |
| Medtronic, Inc. | $14.44 |
| Beta Bionics, Inc. | $11.02 |
| Compensation for services other than consulting (speaking, faculty) | $5,746 |
|---|---|
| Food and Beverage | $166 |
| Travel and Lodging | $60.59 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ascendis Pharma Endocrinology Inc Jun 25, 2025 | Compensation for services other than consulting (speaking, faculty) Yorvipath · Endocrinology | $1,989 |
| Ascendis Pharma Endocrinology Inc Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) Yorvipath · Endocrinology | $1,768 |
| Ascendis Pharma Endocrinology Inc May 9, 2025 | Compensation for services other than consulting (speaking, faculty) Yorvipath · Endocrinology | $1,105 |
| Ascendis Pharma Endocrinology Inc Nov 21, 2025 | Compensation for services other than consulting (speaking, faculty) Yorvipath · Endocrinology | $884 |
| Ascendis Pharma Endocrinology Inc Jul 2, 2025 | Travel and Lodging Yorvipath · Endocrinology · travel to Radnor, PA | $42.00 |
| Ascendis Pharma Endocrinology Inc Jul 2, 2025 | Travel and Lodging Yorvipath · Endocrinology · travel to Radnor, PA | $18.59 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $104,208 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism
Ascendis Pharma Endocrinology Inc · Approved for marketing · NCT05654701 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.